<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVETo evaluate whether LY2605541 results in lower fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG) versus insulin glargine (GL).RESEARCH DESIGN AND METHODSThis 12-week, randomized, open-label, Phase 2 study enrolled patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (<z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A(1c) [A1C] ≤ 10.5%), taking <z:chebi fb="0" ids="6801">metformin</z:chebi> and/or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> with GL or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin once daily </plain></SENT>
<SENT sid="1" pm="."><plain>Patients converted to morning insulin administration during lead-in were randomized 2:1 from GL (n = 248) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin (n = 39) to LY2605541 (n = 195) or GL (n = 95) once daily in the morning.RESULTSAt 12 weeks, FBG (mean ± SE) was similar with LY2605541 and GL (118.2 ± 2.0 mg/dL [6.6 ± 0.1 mmol/L] vs. 116.9 ± 2.7 mg/dL [6.5 ± 0.2 mmol/L], P = 0.433) as was A1C (7.0 ± 0.1 vs. 7.2 ± 0.1%, P = 0.279) </plain></SENT>
<SENT sid="2" pm="."><plain>Intraday blood <z:chebi fb="105" ids="17234">glucose</z:chebi> variability was reduced with LY2605541 (34.4 vs. 39.1 mg/dL [1.9 vs. 2.2 mmol/L], P = 0.031) </plain></SENT>
<SENT sid="3" pm="."><plain>LY2605541 patients had <z:hpo ids='HP_0001824'>weight loss</z:hpo> (-0.6 ± 0.2 kg, P = 0.007), whereas GL patients gained weight (0.3 ± 0.2 kg, P = 0.662; treatment difference: -0.8 kg, P = 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence and rate of both total <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> were comparable between LY2605541 and GL, although, LY2605541 had a 48% reduction in nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> after adjusting for baseline <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (P = 0.021) </plain></SENT>
<SENT sid="5" pm="."><plain>Adverse events were similar across treatments </plain></SENT>
<SENT sid="6" pm="."><plain>Alanine aminotransferase and <z:chebi fb="0" ids="29995">aspartate</z:chebi> aminotransferase remained within <z:mpath ids='MPATH_458'>normal</z:mpath> range but were significantly higher with LY2605541 (P ≤ 0.001).CONCLUSIONSIn patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, LY2605541 and GL had comparable <z:chebi fb="105" ids="17234">glucose</z:chebi> control and total <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> rates, but LY2605541 showed reduced intraday variability, lower nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, and <z:hpo ids='HP_0001824'>weight loss</z:hpo> relative to GL </plain></SENT>
</text></document>